Lack of a Clinically Significant Drug–Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Kanter, Clara T. M. M. de; Blonk, Maren I.; Colbers, Angela; Schouwenberg, B.J.J.W.; Burger, David M.

doi:10.1093/cid/cis824

Cited by 29 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacokinetic/pharmacodynamic (PK/PD) interactions between ART, immunosuppressive drugs, and anti-HCV drugs are frequent [42][43][44][45]. As ritonavir and cobicistat are strong CYP450 inhibitors that can increase many times the AUC of calcineurin inhibitors (ciclosporin and tacrolimus), Efavirenz, a modest CYP450 inducer, has been the preferred antiretroviral for many years [8][9][10].…”

Section: Challengesmentioning

confidence: 99%

See 1 more Smart Citation

Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update

Miró

Stock

Teicher

et al. 2015

Journal of Hepatology

View full text Add to dashboard Cite

Liver transplantation is increasingly performed in selected HIV-infected patients in most developed countries, with excellent results reported in patients with liver diseases unrelated to HCV. In contrast, survival in HCV/HIV-coinfected liver recipients is poorer than in HCV-monoinfected patients, due to more aggressive recurrence of HCV and consequent graft loss and death. Results from American, French, and Spanish cohort studies showed a 5-year survival rate of only 50-55%. Therefore, it is debated whether liver transplantation should be offered to HCV/HIV-coinfected patients. Studies have shown that the variables more consistently associated with poor outcome are: (1) the use of old or HCV-positive donors, (2) dual liver-kidney transplantation, (3) recipients with very low body mass index and (4) less site experience. However, the most effective factor influencing transplantation outcome is the successful treatment of HCV recurrence with anti-HCV. Survival is 80% in patients whose HCV infection resolves. Unfortunately, the rates of sustained virological response with pegylated-interferon plus ribavirin in coinfected recipients are low, particularly for genotype 1 (only 10%). Here we present a non-systematic review of the literature based on our own experience in different liver transplant scenarios. This review covers selection criteria in HIV-infected patients, pre- and post-LT management, donor selection, anti-HCV treatment, drug interactions with antiretrovirals and anti-HCV direct antiviral agents, hepatocellular carcinoma, and liver retransplantation. Recommendations are rated. Finally, we explain how the introduction of new effective and more tolerable direct antiviral agents may improve significantly the outcome of HCV/HIV-coinfected liver recipients.

show abstract

Section: Challengesmentioning

confidence: 99%

“…Other major PK/PD interactions have been recognized with the HCV NS3/4A PIs boceprevir and telaprevir [42,44,45]. These drugs had significant and non-predictable interactions with antiretrovirals, particularly non-NRTIs and HIV PIs, thus precluding many combinations.…”

Section: Challengesmentioning

confidence: 99%

Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update

Miró

Stock

Teicher

et al. 2015

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…95 In contrast, raltegravir may be used with both HCV agents without dosage adjustment. 96,97 Both antiretrovirals and current HCV treatment have multiple adverse effects. For instance, pegylated interferon and ribavirin have toxic effects that overlap with those of zidovudine and efavirenz, resulting in additive anemia and CNS effects, including depression, mood changes, and suicidality.…”

Section: Hepatitis Cmentioning

confidence: 99%

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines

Tseng

Foisy

Hughes

et al. 2012

CJHP

View full text Add to dashboard Cite

“…The protease inhibitor BOC decreased the exposure of all protease inhibitors; ATV/ritonavir did not significantly affect BOC exposure, whereas BOC was reduced by 45% and 32% when co-administered with LPV/ritonavir and DRV/ritonavir, respectively [75] . In a recent study no significant drug interaction between BOC and raltegravir was found in healthy volunteers [76] . The role of ritonavir in the drug interactions between TPV and ATV was recently investigated.…”

Section: Art Management In Hiv/hcv Coinfected Patients During Treatmementioning

confidence: 92%

Treatment of chronic hepatitis C in patients with HIV/HCV coinfection

Coppola

Martini

Pisaturo

et al. 2015

WJV

View full text Add to dashboard Cite

frequent causes of comorbidity and mortality in the human immunodeficiency virus (HIV) population, and liver-related mortality is now the second highest cause of death in HIV-positive patients, so HCV infection should be countered with adequate antiviral therapy. In 2011 began the era of directly acting antivirals (DAAs) and the HCV NS3/4A protease inhibitors telaprevir and boceprevir were approved to treat HCV-genotype-1 infection, each one in combination with pegylated interferon alfa (Peg-IFN) + ribavirin (RBV). The addition of the first generation DAAs, strongly improved the efficacy of antiviral therapy in patients with HCVgenotype 1, both for the HCV-monoinfected and HIV/ HCV coinfected, and the poor response to Peg-IFN + RBV in HCV/HIV coinfection was enhanced. These treatments showed higher rates of sustained virological response than Peg-IFN + RBV but reduced tolerability and adherence due to the high pill burden and the several pharmacokinetic interactions between HCV NS3/ 4A protease inhibitors and antiretroviral drugs. Then in 2013 a new wave of DAAs arrived, characterized by high efficacy, good tolerability, a low pill burden and shortened treatment duration. The second and third generation DAAs also comprised IFN-free regimens, which in small recent trials on HIV-positive patients have shown comforting preliminary results in terms of efficacy, tolerability and adherence.

show abstract

Lack of a Clinically Significant Drug–Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Abstract: NCT01288417.

Cited by 29 publications

References 15 publications

Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update

Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines

Treatment of chronic hepatitis C in patients with HIV/HCV coinfection

Contact Info

Product

Resources

About